Online inquiry

IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9459MR)

This product GTTS-WQ9459MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets KIR3DL2 gene. The antibody can be applied in Lymphoma, cutaneous T cell (CTCL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001242867.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3812
UniProt ID P43630
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9459MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2958MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ10234MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ1947MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ2873MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ15479MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ6449MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ694MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ10962MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW